BioCentury | Apr 29, 2010
Finance

Beta testing in diabetes

...INGAP peptide ), a synthetic version of a portion of Ingap, now is being developed by Exsulin...
...Del. Eastern Virginia Medical School , Norfolk, Va. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Exsulin...
BioCentury | Sep 21, 2009
Clinical News

Exsulin: Phase II started

...double-blind, placebo-controlled, North American Phase II trial (E-201) to evaluate 100 or 200 mg subcutaneous Exsulin...
...been treated with insulin for >2 years. Exsulin Corp. , Minneapolis, Minn. Product: Exsulin ( INGAP peptide...
BioCentury | Aug 24, 2009
Clinical News

Exsulin: Phase II data

...placebo. No significant changes were observed in the 300 mg/day Exsulin arm. Both doses of Exsulin...
...the INGAP peptide from GMP Companies Inc. (Fort Lauderdale, Fla.). Exsulin Corp. , Minneapolis, Minn. Product: Exsulin...
...from GMP Companies Inc. (Fort Lauderdale, Fla.). Exsulin Corp. , Minneapolis, Minn. Product: Exsulin ( INGAP peptide...
BioCentury | Aug 24, 2009
Clinical News

Exsulin: Phase II data

...placebo. No significant changes were observed in the 300 mg/day Exsulin arm. Both doses of Exsulin...
...the INGAP peptide from GMP Companies Inc. (Fort Lauderdale, Fla.). Exsulin Corp. , Minneapolis, Minn. Product: Exsulin...
...from GMP Companies Inc. (Fort Lauderdale, Fla.). Exsulin Corp. , Minneapolis, Minn. Product: Exsulin ( INGAP peptide...
BioCentury | Aug 19, 2009
Clinical News

Exsulin reports diabetes data

...Corp. (Minneapolis, Minn.) reported mixed results from a pair of double-blind Phase II trials of Exsulin...
...1 trial to treat Type I diabetes in 63 patients, once-daily injections of 600 mg Exsulin...
...SPIRIT 2 trial in 126 patients with Type II diabetes, once-daily injections of 600 mg Exsulin...
BioCentury | May 12, 2008
Company News

DiaKine, Kinexum Metabolics Inc. deal

The companies partnered to develop a combination of DiaKine’s lisofylline and Kinexum’s islet neogenesis associated protein (INGAP) peptide to treat Type I diabetes. The companies will co-own the resulting product. Financial terms were not disclosed....
BioCentury | Apr 14, 2008
Clinical News

Cell Therapeutics, DiaKine preclinical data

...led to a 70% complete remission rate and eliminated the need for insulin, Lisofylline or INGAP peptide...
Items per page:
1 - 7 of 7